Drugs / SLV317
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00160862 | May → Nov 2003 | — | Heidelberg University | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SLV317 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00160862 ↗ |
| Action | Inhibit | “NK-1 Antagonism of SLV317 in Humans” NCT00160862 ↗ |
| Route | Oral | “single oral dose of 250 mg SLV 317” NCT00160862 ↗ |